Self-amplifying COVID-19 mRNA vaccination induces longitudinally enhanced antibody function in a Phase 3 trial

Nature·Mar 30

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A phase 3 trial has found that a self-amplifying COVID-19 mRNA vaccination induces enhanced antibody function over time. Research on COVID-19 vaccines, including mRNA and other platforms, is ongoing, with studies exploring their immune responses, durability, and applications in various populations. The outcomes of these studies may contribute to the development of effective and long-lasting COVID-19 vaccines.

Full coverage

COVID-19 mRNA vaccines: a prospective outlook from technological innovation to clinical practice

Frontiers·May 22

Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms

Nature·Dec 8

Homologous MVA and heterologous DREP/MVA vaccine regimens induce robust and durable immune responses against SARS-CoV-2 | Scientific Reports

Nature·Apr 9

Predicting age-related determinants of heterogeneous outcomes to COVID-19 mRNA vaccines through mathematical modelling

medRxiv·Feb 18

Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity

Wiley Online Library·Nov 3

Nucleic acid vaccines: innovations, efficacy, and applications in at-risk populations

Frontiers·May 14

Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial

Nature·Sep 24

Advancing mRNA technologies for therapies and vaccines: An African context

Frontiers·Feb 8

View original report at Nature ↗

Fetching the latest headlines…